MDL | - |
---|---|
Molecular Weight | 326.31 |
Molecular Formula | C15H14N6O3 |
SMILES | O=C(C1=C(CN2C)N(C=N1)C3=CC=C(N=[N+]=[N-])C=C3C2=O)OCC |
Ro15-4513 usually acts as a partial inverse agonist at GABA A receptors, except an agonist for α4 and α6 subunit-containing ones [3] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Ro 15-4513 (i.p.; 3 mg/kg; 10 min before being tested) completely inhibits the ethanol-induced (1.8 g/kg) reduction in total locomotor activity and partly the reduction in rearing
[2]
.
Ro 15-4513 (i.p.; 3 mg/kg; 15 min before administration of 1.5 g/kg ethanol) reverses ethanol-induced sedation in GABA
A
receptor δ subunit-deficient mice
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: | Male C57BL/6J mice [2] |
Dosage: | 3 mg/kg |
Administration: | I.p.; 10 min before being tested |
Result: | Completely inhibited the ethanol-induced reduction in total locomotor activity and partly the reduction in rearing. |
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT03507569 | Hoffmann-La Roche |
Autism Spectrum Disorder
|
April 24, 2018 | Phase 1 |
Solid
Room temperature in continental US; may vary elsewhere.
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)